Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase I Clinical Trial on Safety, Tolerability and Immunogenicity of HIV Therapeutic DNA Vaccine (ICVAX) in Clinically Stable HIV Patients Under ART

NCT06253533 is registered in ClinicalTrials.gov with Immuno Cure Holding (HK) Limited as lead sponsor.

NCT NCT06253533
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06253533 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase I Clinical Trial on Safety, Tolerability and Immunogenicity of HIV Therapeutic DNA Vaccine (ICVAX) in Clinically Stable HIV Patients Under ART
Lead sponsor
Immuno Cure Holding (HK) Limited
Phase
Phase 1
Overall status
Completed
Start date
February 14, 2023
Completion date
August 7, 2025
Enrollment
45 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

human immunodeficiency virus, human immunodeficiency virus i infection